This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. There are no more editions this year, but you can keep up with biopharma news by signing up for STAT’s The Readout newsletter.
A status check on immunotherapies
It was 10 years ago that Keytruda and Opdivo were approved in their first indications. One of the pervading themes of this year’s ESMO was a reflection on all that the drugs have done, and all that immunotherapy still needs to achieve.
The conference included a decade’s worth of data from some of the early Keytruda and Opdivo trials, with the takeaway being that roughly 50% of patients with metastatic melanoma will now survive over the long term.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
